Meningitis Clinical Trial
Official title:
Immunogenicity and Safety of a Single Dose of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects
Verified date | May 2013 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Japan: Pharmaceuticals and Medical Devices Agency |
Study type | Interventional |
This study is designed to assess the safety and immunogenicity of a single dose of
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
(SP284) to support registration of the product in Japan.
Primary Objective:
- To describe the seroprotection rate [% of subjects with serum bactericidal assay using
baby rabbit complement (SBA-BR) ≥1:128] to meningococcal antigens (serogroups A, C, Y
and W-135) following vaccination with SP284 vaccine in subjects 2 through 55 years of
age
Secondary Objectives:
- To describe the safety following receipt of SP284 vaccine in subjects 2 through 55
years of age
- To describe the immune responses to meningococcal antigens (serogroups A, C, Y and
W-135) following vaccination with SP284 vaccine in subjects 2 through 55 years of age.
Status | Completed |
Enrollment | 200 |
Est. completion date | December 2012 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 2 Years to 55 Years |
Eligibility |
Inclusion Criteria: - Aged 2 through 55 years on the day of inclusion - For subjects = 20 years of age: Informed consent form has been signed and dated by the subjects. For subjects 2 to 19 years of age: Informed consent form has been signed and dated by the parent(s) or other legal representative. Also subjects 7 to 11 years of age will provide assent and subjects 12 to 19 years of age will provide written assent form. - Able to attend all scheduled visits and to comply with all trial procedures - For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. Exclusion Criteria: - Any acute and/or serious disease/illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion - History of meningococcal diseases, confirmed either clinically, serologically, or microbiologically - Known systemic hypersensitivity to any of the vaccine components, or history of a life threatening reaction to a vaccine containing the same substances of the study vaccine - Known or suspected congenital or current/ previous acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroids therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months) - Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial inclusion - Planned participation in another clinical trial during the present trial period - Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response - Receipt of any vaccine within the four weeks preceding the trial vaccination, except for influenza vaccination, which may be received at least two weeks before the study vaccine - Planned receipt of any vaccine during the trial period - Clinical or known serological evidence of systemic illness including hepatitis B, hepatitis C and/or human immunodeficiency virus (HIV) infection - Ineligible according to the investigator's clinical judgment - Known pregnancy, or suspected pregnancy or a positive (serum and/or urine) pregnancy test - Currently breast feeding a child - Known thrombocytopenia, contraindicating intramuscular (IM) vaccination - Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination - Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily - Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures - Identified as employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family member (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the Investigator - Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine - History of Guillain-Barré Syndrome. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Sanofi Pasteur, a Sanofi Company |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:128 Following Vaccination With One Dose of Menactra® Vaccine | Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). Sero protection was defined as SBA-BR titer of = 1:128. | 28 Days post-vaccination | No |
Secondary | Number of Participants With Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers of >=1:8 Following Vaccination With One Dose of Menactra® Vaccine | Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). | 28 Days post-vaccination | No |
Secondary | Number of Participants With a 4-Fold Rise in Serum Bovine Albumin Baby Rabbit (SBA-BR) Titers on Day 28 From Day 0 Following Vaccination With One Dose of Menactra® Vaccine. | Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). | 28 Days post-vaccination | No |
Secondary | Serum Bovine Albumin Baby Rabbit (SBA-BR) Geometric Mean Titers Following Vaccination With One Dose of Menactra® Vaccine | Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). | Days 0 and 28 post-vaccination | No |
Secondary | Serum Bovine Albumin Baby Rabbit (SBA-BR) Geometric Mean of Individual Titer Ratio Following Vaccination With One Dose of Menactra® Vaccine | Functional antibody activity against meningococcal serogroups A, C, Y and W-135 antigens were determined by using a serum bovine assay using a baby rabbit complement (SBA-BR). | 28 Days post-vaccination | No |
Secondary | Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reactions Following Vaccination With One Dose of Menactra® Vaccine | Solicited injection site reactions: Pain, Erythema and Swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, and Myalgia. Grade 3 solicited reactions were defined as: Pain incapacitating (children) and prevents daily activities (adolescents and adults). Fever = 39.0°C; Headache, Malaise and Myalgia, significant, prevents daily activities. |
Day 0 up to Day 28 post-vaccination | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03445416 -
Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men
|
N/A | |
Completed |
NCT02526394 -
Pertussis and Meningitis C Concomitant Vaccination in Adolescents
|
Phase 4 | |
Completed |
NCT01442675 -
Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
|
Phase 2 | |
Completed |
NCT00539032 -
Immunology and Safety of Menactra® in Children in Saudi Arabia
|
Phase 3 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Recruiting |
NCT05496673 -
Meningitis: Burden, Causes, Screening and Prevention in Rural Northern Uganda
|
N/A | |
Completed |
NCT02003495 -
Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine
|
Phase 3 | |
Recruiting |
NCT00901602 -
Lebanese Interhospital Pneumococcal Surveillance Program
|
||
Completed |
NCT00850603 -
Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®
|
Phase 4 | |
Completed |
NCT02591290 -
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
|
Phase 4 | |
Completed |
NCT03112031 -
Treatment With Tamoxifen in Cryptococcal Meningitis
|
Phase 2 | |
Completed |
NCT02881957 -
Hypovitaminosis D in Neurocritical Patients
|
Phase 2/Phase 3 | |
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Completed |
NCT03378258 -
Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.
|
||
Recruiting |
NCT05637645 -
Different Approaches of Spinal Anesthesia in Patients Undergoing Cesarean Section
|
N/A | |
Completed |
NCT02841254 -
Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies
|
N/A | |
Completed |
NCT02003313 -
Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine
|
Phase 3 | |
Recruiting |
NCT01619462 -
Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children
|
Phase 3 | |
Completed |
NCT01239043 -
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
|
Phase 2 | |
Completed |
NCT00495690 -
Impact of Daily Zinc Supplementation to Infants Born With Low Birth Weight on Death and Severe Disease
|
Phase 3 |